{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:02:54Z","timestamp":1791576174071,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005923","name":"IASLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.03.011","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T13:20:44Z","timestamp":1621430444000},"page":"211-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics"],"prefix":"10.1016","volume":"151","author":[{"given":"Laura","family":"Mezquita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4504-4520","authenticated-orcid":false,"given":"Isabel","family":"Preeshagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Saravia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-3102","authenticated-orcid":false,"given":"Wungki","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-5554","authenticated-orcid":false,"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Martin-Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-320X","authenticated-orcid":false,"given":"Jose C.","family":"Ruffinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Carnio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Blanc-Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-5076","authenticated-orcid":false,"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-2992","authenticated-orcid":false,"given":"Fabrizio","family":"Tabb\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-5149","authenticated-orcid":false,"given":"Maria Lucia","family":"Reale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-9748","authenticated-orcid":false,"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-899X","authenticated-orcid":false,"given":"Peter","family":"Sawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0533-0423","authenticated-orcid":false,"given":"Jeffrey","family":"Girshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-370X","authenticated-orcid":false,"given":"Andrew J.","family":"Plodkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Charrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Naigeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Rossoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnnaPaola","family":"Mariniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-041X","authenticated-orcid":false,"given":"Lydie","family":"Cassard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Chaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10027","key":"10.1016\/j.ejca.2021.03.011_bib1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2021.03.011_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejca.2021.03.011_bib3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ejca.2021.03.011_bib4","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2021.03.011_bib5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejca.2021.03.011_bib6","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.03.011_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.03.011_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2018.11.002","article-title":"Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer","volume":"106","author":"Prelaj","year":"2019","journal-title":"Eur J Canc"},{"issue":"23","key":"10.1016\/j.ejca.2021.03.011_bib9","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2217\/fon-2020-0182","article-title":"Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations","volume":"16","author":"Riudavets","year":"2020","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.03.011_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.23736\/S1824-4785.20.03250-1","article-title":"The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors","volume":"64","author":"Benitez","year":"2020","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.ejca.2021.03.011_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2021.03.011_bib12","doi-asserted-by":"crossref","first-page":"14381","DOI":"10.1038\/ncomms14381","article-title":"Neutrophils dominate the immune cell composition in non-small cell lung cancer","volume":"8","author":"Kargl","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2021.03.011_bib13","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3389\/fimmu.2019.01912","article-title":"Neutrophil maturity in cancer","volume":"10","author":"Mackey","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2021.03.011_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/1759-7714.12952","article-title":"Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: a hypothesis-generating study","volume":"10","author":"Soda","year":"2019","journal-title":"Thorac Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2021.03.011_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41416-019-0643-y","article-title":"Association of the prognostic model iSEND with PD-1\/L1 monotherapy outcome in non-small-cell lung cancer","volume":"122","author":"Park","year":"2020","journal-title":"Br J Canc"},{"issue":"24","key":"10.1016\/j.ejca.2021.03.011_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130850","article-title":"Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC","volume":"4","author":"Kargl","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejca.2021.03.011_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.12.017","article-title":"Circulating innate immune markers and outcomes in treatment-na\u00efve advanced non-small cell lung cancer patients","volume":"108","author":"Charrier","year":"2019","journal-title":"Eur J Canc"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2021.03.011_bib18","article-title":"Neutrophils as myeloid-derived suppressor cells","volume":"48","author":"Aarts","year":"2018","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"10.1016\/j.ejca.2021.03.011_bib19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/jamaoncol.2019.1747","article-title":"Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer","volume":"5","author":"Kazandjian","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.03.011_bib20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jtho.2019.04.006","article-title":"Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials","volume":"14","author":"Sorich","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2021.03.011_bib21","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.03.011_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Canc"},{"issue":"3","key":"10.1016\/j.ejca.2021.03.011_bib23","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s12325-020-01229-w","article-title":"Neutrophil-to-Lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective multicenter study","volume":"37","author":"Russo","year":"2020","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.ejca.2021.03.011_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22964","article-title":"Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab","volume":"33","author":"Liu","year":"2019","journal-title":"J Clin Lab Anal"},{"issue":"12","key":"10.1016\/j.ejca.2021.03.011_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121954","article-title":"EPSILoN: a prognostic score for immunotherapy in advanced non-small-cell lung cancer: a validation cohort","volume":"11","author":"Prelaj","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejca.2021.03.011_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CJI.0000000000000297","article-title":"Blood immune cell biomarkers in patient with lung cancer undergoing treatment with checkpoint blockade","volume":"43","author":"M\u00f6ller","year":"2020","journal-title":"J Immunothery"},{"issue":"10","key":"10.1016\/j.ejca.2021.03.011_bib27","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00432-019-02982-4","article-title":"Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers","volume":"145","author":"Li","year":"2019","journal-title":"J Canc Res Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.03.011_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219060","article-title":"Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers","volume":"14","author":"Dusselier","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2021.03.011_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919839928","article-title":"Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients","volume":"11","author":"Passiglia","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.03.011_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/psp4.12578","article-title":"Longitudinal tumor size and neutrophil-to-lymphocyte ratio are prognostic biomarkers for overall survival in patients with advanced non-small cell lung cancer treated with durvalumab","volume":"10","author":"Gavrilov","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ejca.2021.03.011_bib31","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3389\/fimmu.2019.02144","article-title":"Neutrophils as suppressors of T cell proliferation: does age matter?","volume":"10","author":"Aarts","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.ejca.2021.03.011_bib32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/jamaoncol.2020.1634","article-title":"Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer","volume":"6","author":"Kas","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.03.011_bib33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/PO.20.00021","article-title":"Comparison of fast-progression, hyperprogressive disease, and early deaths in advanced non\u2013small-cell lung cancer treated with PD-1\/PD-L1 inhibitors or chemotherapy","volume":"4","author":"Ferrara","year":"2020","journal-title":"JCO Precision Oncology"},{"issue":"11","key":"10.1016\/j.ejca.2021.03.011_bib34","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.03.011_bib35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2967\/jnumed.119.237768","article-title":"Hyper-progressive disease in patients with non-small cell lung cancer treated with checkpoint inhibitors: the role of 18F-FDG PET\/CT","volume":"61","author":"Castello","year":"2020","journal-title":"J Nucl Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:19Z","timestamp":1760733139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921001787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":35,"alternative-id":["S0959804921001787"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}